Chris Ryan

Key Takeaways Epcoritamab monotherapy improved PFS versus investigator's choice CIT in relapsed/refractory LBCL and increased CR rates, while OS neutrality appeared confounded by COVID-19 mortality and post-protocol therapy. Frontline high-risk DLBCL benefited from tafasitamab/lenalidomide plus R-CHOP, achieving significantly better PFS and EFS than R-CHOP alone without reducing R-CHOP relative dose intensity. In vivo BCMA CAR-T generation with KLN-1010 produced 100% ORR and 10⁻⁵ MRD-negative marrow responses, with no grade ≥3 CRS and outpatient-feasible tolerability. Teclistamab monotherapy in MajesTEC-9 delivered marked PFS and OS advantages over PVd/Kd in 1–3 prior-line, daratumumab- and lenalidomide-refractory RRMM, alongside deeper response rates. CALR-mutant myelofibrosis showed spleen, symptom, anemia, and allele-burden reductions with INCA033989, with cytopenias mainly in predisposed patients and forthcoming frontline/second-line studies anticipated. SHOW MORE

Key Takeaways Indications include Isa-Pd after ≥1 prior line (lenalidomide plus PI), Isa-Kd after 1–3 prior lines, and Isa-VRd for transplant-ineligible newly diagnosed disease. IRAKLIA randomized RRMM patients 1:1 to SC 1400 mg vs IV 10 mg/kg with Pd, with ORR and cycle-6 day-1 Ctrough as coprimary noninferiority end points. Efficacy was maintained with SC delivery: ORR 71.1% vs 70.5% and VGPR-or-better 46.4% vs 45.9%, alongside noninferior steady-state exposure (GMR 1.532). OBDS is a single-use, user-filled wearable injector with concealed needle, weight-independent flat dosing, no hyaluronidase, and individualized flow based on interstitial pressure. Safety showed IRRs of 1.5% with SC vs 25.0% with IV, while overall TEAEs, grade ≥3 events, discontinuations, and grade 5 events were broadly similar. SHOW MORE

Key Takeaways Expanded FDA indications were supported by CARTITUDE-4 (HR 0.29; 30-month PFS 59.4% vs 25.7%) and KarMMa-3 (PFS 13.8 vs 4.4 months; HR 0.49). Estimates suggest 60%–80% of patients may be eligible for CAR T at first relapse, yet only 10%–30% receive it, prompting a shift toward earlier referral. Sequencing strategy increasingly favors CAR T earlier, preserving post–CAR T options such as bispecific antibodies; using a bispecific first may limit subsequent BCMA-targeted choices. Neurotoxicity risk communication is pivotal; Parkinsonism rates with contemporary cilta-cel experience are cited as <1%, and effective bridging/debulking to MRD negativity may improve tolerance. Access constraints are dominated by referral loss, misconceptions, caregiver logistics, and travel burden; virtual intake visits and community engagement may meaningfully increase treatment throughput. SHOW MORE

Key Takeaways Traditional approval covers RET fusion–positive solid tumors in patients aged ≥2 years after prior systemic therapy failure or when no satisfactory alternatives exist, contingent on FDA-approved companion diagnostic testing. Conversion from accelerated to regular approval reflects confirmatory data from LIBRETTO-001 and LIBRETTO-121, alongside established activity in RET fusion–positive NSCLC and thyroid malignancies. In LIBRETTO-001 (n=75) non-NSCLC/non-thyroid RET fusion tumors, ORR was 47% (95% CI, 35%-59%) with median DOR 24.5 months (95% CI, 11.2-49.1). LIBRETTO-121 demonstrated activity across rare histologies, including congenital infantile fibrosarcoma and spindle cell sarcoma, and also supported responses in RET fusion–positive thyroid cancer. SHOW MORE

PGA Golf Coach Chris Ryan shares a two-stage drill that has produced some of the fastest ball striking improvements he has seen in his students.

Key Takeaways Pooled TRUST-I/II data showed taletrectinib achieved ORR 89.8%, median DOR 49.7 months, and median PFS 46.1 months in TKI-naïve ROS1+ NSCLC, with manageable hepatic and GI TEAEs. Clinical adoption is accelerated by FDA approval (June 2025) and an sNDA under review for updated outcomes in both TKI-naïve and pretreated ROS1+ populations. Zidesamtinib generated ORRs of 41% post-repotrectinib and 47% post-taletrectinib, with notable activity in ROS1 G2032R, though mutation-specific PFS remains an unmet data need. Seven-year CROWN results maintained unprecedented lorlatinib durability (median PFS NR; 55% 7-year PFS), yet patient-level toxicity tradeoffs complicate elective switching from alectinib despite mature survival data. Earlier-stage expansion is controversial: TRUST-IV tests adjuvant taletrectinib vs placebo, while neoadjuvant lorlatinib in LORIN produced 47% pCR, 81% MPR, and high conversion-to-resection rates. SHOW MORE

Key Takeaways Tentative approval supports bioequivalent 100-mg and 150-mg olaparib formulations intended to match all approved Lynparza labeling indications. Ovarian cancer use includes first-line maintenance for BRCA-mutated disease and bevacizumab-based maintenance for HRD-positive tumors defined by BRCA mutation and/or genomic instability. Breast cancer indications cover adjuvant therapy for high-risk early HER2-negative gBRCA disease post-chemotherapy and treatment of metastatic HER2-negative gBRCA disease after chemotherapy, with endocrine therapy considerations. Additional labeled settings include maintenance gBRCA metastatic pancreatic cancer after ≥16 weeks of platinum and mCRPC treatment for HRR-mutated disease post-enzalutamide/abiraterone, plus BRCA-mutated mCRPC with abiraterone and steroids. Patient selection across indications requires use of an FDA-approved companion diagnostic for olaparib. SHOW MORE

(COLORADO SPRINGS) — Following a weather delay, nothing doing on the scoreboard until late in the night as Switchbacks FC’s Khori Bennett drilled a header, before tacking on an insurance goal over Miami FC 2-0, on Wednesday at Weidner Field. The Switchbacks have won three straight matches and six of their last eight as they […]

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.